Cost-Effectiveness Data Missing From Drugs That Cost Medicare $50 Billion
A report notes a third of Medicare Part D costs in 2016 were for buying drugs that lacked quality analysis of their cost-effectiveness. Stat, meanwhile, reports on the ineffectiveness of a generics-boosting California law banning coupons for brand-name drugs.